Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618002004246
Ethics application status
Approved
Date submitted
29/11/2018
Date registered
13/12/2018
Date last updated
22/05/2023
Date data sharing statement initially provided
13/12/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
The BP2 (Blood Pressure Postpartum) study: a 3-arm, randomised trial of follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive disorders of pregnancy
Scientific title
Improving maternal and infant cardiovascular health trajectories after hypertensive pregnancy: a 3 arm, randomised lifestyle intervention trial
Secondary ID [1] 296466 0
None
Universal Trial Number (UTN)
U1111-1218-5078
Trial acronym
BP2
Linked study record
N/A

Health condition
Health condition(s) or problem(s) studied:
Preeclampsia 310504 0
Gestational Hypertension 310505 0
Chronic Hypertension in pregnancy 310506 0
Condition category
Condition code
Cardiovascular 309217 309217 0 0
Hypertension
Public Health 309218 309218 0 0
Health promotion/education
Reproductive Health and Childbirth 309219 309219 0 0
Fetal medicine and complications of pregnancy

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
At 6 months postpartum (pp) all participants (women after preeclampsia, gestational hypertension, or chronic hypertension) complete validated questionnaires: NSW Population Health Survey (by telephone), Infant Feeding behaviours, Health-related Quality of Life (EQ-5D-5L), Ages and Stages, Edinburgh Postnatal Depression Score, Generalised Anxiety Disorder and a study designed maternal and infant health questionnaire about health since the birth (hard copy or online). Pregnancy, labour, birth and infant details will be recorded from the hospital maternity database. Blood and urine testing will be done and repeated at 12 months pp.
After completion of baseline questionnaires, women are randomised into one of 3 groups with interventions as below.

Optimised Usual Care (Group 1):
• report their weight, height, and waist circumference to the research staff
• sent package containing readily available information about cardiovascular health after hypertensive disorder of pregnancy (HDP). This information includes:
1. The Heart Foundation infographic titled 'Did you have high blood pressure during pregnancy?'(www.heartfoundation.org.au),
2. The NSW Get Healthy Service (GHS) a free service of phone call counselling to work towards healthy lifestyle changes (www.gethealthynsw.com.au)
3. The link to the 'My Baby Now' app which is free and available on IoS and android phones. This app offers information regarding the baby's development and nutrition advice through to 9-12 months of age.
• visit their GP with their infant at 6 months pp for BP check, weight and their infant’s weight, height and head circumference. GP/medical centre will be sent an information package to assist with this visit. This package will contain an explanatory cover letter, correspondence from the pregnancy/birth care including the hospital discharge summary, the Heart Foundation Information for GPs titled 'Hypertensive Disorders of Pregnancy and Cardiovascular Disease: A guide for GPs' (this consists of two brochures: General Facts and Postpartum Assessment, both freely available on the Heart foundation Website), a copy of the information pack given to the woman (see above) and a copy of the woman's signed study consent form. Details of the GP visit will be sent to the research staff to complete data collection. A reminder phone will be made to the participants regarding booking this appointment with their GP/medical centre.

Brief Education Intervention (Group 2):
• attend hospital with their infant at 6 months pp for maternal measures: peripheral and central BP, height, weight, waist circumference, body composition, and infant measures: weight, length, head and abdominal circumference, blood pressure
• a single 30 minute consultation with an obstetric medicine physician, who will review the personal history and examination findings, educate regarding long-term health implications of HDP, and address cardiovascular risk by offering advice on lifestyle and behavioural change such as quit smoking, exercise and healthy diet.
• see a dietitian for a single 30 minute appointment to review of diet and physical activity, infant’s feeding patterns, and discussion on healthy eating and physical activity.
A reminder text message will be sent a few days prior to theses appointments to remind the participant of the appointment. Data from these visits will be sent to the researcher for data collection and entry into database.

Extended lifestyle intervention (Group 3)
In addition to the intervention for Group 2, research staff will enroll Group 3 participants in the NSW Get Healthy Service (GHS). GHS will then provide, over a 6 month period, up to 13 coaching calls that include initial goal setting and then working towards lifestyle behaviour change goals during program enrollment. A follow-up phone call and text message will be made by trial research staff 2-3 weeks after enrollment into GHS to check that contact has been made between GHS and the participant and that the participant has commenced with the GHS program. Adherence to the GHS will be assessed at the 12 month follow-up visit by the GHS staff who will liaise with study researchers. GHS staff will use the Service records to report on which GHS clients participated in the trial (whether in Group 1, 2, or 3), provide data on whether participants completed (a) initial GHS process (b) full 6-month GHS service (c) for those trial participants who initiated but did not complete, point of GHS termination and any know reason.

Semi structured interviews will be conducted with women from all groups between the 6 and 12 month visits. These interviews will explore the barriers and enablers to adopting healthy eating and physical activity behaviours post-partum and women will be asked their views of the intervention to better understand their engagement. All women will be invited to participate via a question at the end of the women’s 6 month survey and we will purposefully sample from each of the groups to ensure that views are captured about each arm of the intervention.
Intervention code [1] 312986 0
Lifestyle
Intervention code [2] 312988 0
Early detection / Screening
Intervention code [3] 312989 0
Behaviour
Comparator / control treatment
Optimised Usual Care (Group 1-Control Group):
Complete questionnaires: NSW Population Health Survey (by telephone), Infant Feeding behaviours, Health-related Quality of Life (EQ-5D-5L), Ages and Stages, Edinburgh Postnatal Depression Score, Generalised Anxiety Disorder and a study designed maternal and infant health questionnaire about health since the birth (hard copy or online). Pregnancy, labour, birth and infant details will be recorded from the hospital maternity database. Blood and urine testing will be done and repeated at 12 months pp.
Report their weight, height, and waist circumference to research staff
Sent package containing information about cardiovascular health after hypertensive disorder of pregnancy (HDP), Get Healthy Service, and link to Growing Healthy/My Baby now app
Visit their GP with their infant at 6 months pp for BP check, weight and their infant’s weight, height and head circumference.
Control group
Active

Outcomes
Primary outcome [1] 308200 0
Change in systolic blood pressure measured using the average of three measurements from a validated automated blood pressure device; the Omron HEM-907
Timepoint [1] 308200 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Primary outcome [2] 308229 0
Maternal lifestyle behaviour change (LBC) as assessed by decrease in weight (4kg or more) measured by research staff using digital scales.
Timepoint [2] 308229 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Primary outcome [3] 308377 0
Maternal lifestyle behaviour change (LBC) as assessed by a decrease in waist circumference (2cm or more) measured with a measuring tape around the narrowest part of the torso.
Timepoint [3] 308377 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Secondary outcome [1] 354308 0
Lifestyle behaviour change measures assessed by the self-reported NSW Population Health survey questions
Timepoint [1] 354308 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [2] 354309 0
Change in average blood pressure measured using the average of three measurements from a validated automated blood pressure device; the Omron HEM-907

.
Timepoint [2] 354309 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Secondary outcome [3] 354310 0
Infant measures recorded in 'My Personal Health Record' (Blue Book): weight.
Timepoint [3] 354310 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Secondary outcome [4] 354311 0
Maternal serological measures assessed by measuring CRP.
Timepoint [4] 354311 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [5] 354312 0
Maternal vascular function measures: central arterial pressure using SphygmoCor applanation tanometry,
Timepoint [5] 354312 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values).
Secondary outcome [6] 354313 0
Economic analysis
A cost-effectiveness analysis from the perspective of the healthcare system will be undertaken alongside the RCT. The primary economic outcome will be the incremental cost per case of BP and weight/waist circumference reduction achieved in Groups 2 and 3 during the study time period.
Timepoint [6] 354313 0
At 12 months postpartum
Secondary outcome [7] 354314 0
Women’s satisfaction with care measured using the self reported experience measure (PREM) incorporating elements of the Adherence to a Healthy Lifestyle, Burden of Treatment, and CSQ-8 Client Satisfaction Questionnaire.
Timepoint [7] 354314 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [8] 354789 0
Change in weight. Weight measured by researcher using digital scales
Timepoint [8] 354789 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [9] 354790 0
Change in waist circumference. Waist circumference measured by researcher using measuring tape around the narrowest part of the participant's torso.
Timepoint [9] 354790 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [10] 354791 0
Infant measures recorded in 'My Personal Health Record' (Blue Book): height.
Timepoint [10] 354791 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [11] 354792 0
Infant measures recorded in 'My Personal Health Record' (Blue Book): head circumference
Timepoint [11] 354792 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [12] 354793 0
Infant measures recorded in 'My Personal Health Record' (Blue Book): abdominal circumference
Timepoint [12] 354793 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [13] 354795 0
Maternal serological measures assessed by measuring fasting insulin/glucose.
Timepoint [13] 354795 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [14] 354796 0
Maternal serological measures assessed by measuring fasting cholesterol/triglyceride.
Timepoint [14] 354796 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [15] 354797 0
Maternal serological measures assessed by measuring liver function.
Timepoint [15] 354797 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [16] 354798 0
Maternal serological measures assessed by measuring haemoglobin.
Timepoint [16] 354798 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [17] 354799 0
Maternal serological measures assessed by measuring platelets.
Timepoint [17] 354799 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [18] 354800 0
Maternal urine measures assessed by measuring eGFR
Timepoint [18] 354800 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [19] 354801 0
Maternal urine measures assessed by measuring albumin:creatinine ratio.
Timepoint [19] 354801 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [20] 354802 0
Maternal vascular function measure: pulse wave velocity using SphygmoCor applanation tanometry,
Timepoint [20] 354802 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [21] 354803 0
Maternal vascular function measure: augmentation index using SphygmoCor applanation tanometry,
Timepoint [21] 354803 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [22] 354804 0
Maternal vascular function measure performed using blood inflammatory cytokines
Timepoint [22] 354804 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)
Secondary outcome [23] 354805 0
Women’s satisfaction with care: a qualitative study to explore women’s experience of each aspect of the interventions. Semi structured interviews will be conducted with women from all groups between the 6 and 12 month visits. These interviews will explore the barriers and enablers to adopting healthy eating and physical activity behaviours post-partum and women will be asked their views of the intervention to better understand their engagement. All women will be invited to participate via a question at the end of the women’s 6 month survey and we will purposefully sample from each of the groups to ensure that views are captured about each arm of the intervention. Each interview will be digitally recorded (audio only) and later transcribed verbatim in preparation for a thematic analysis.
Timepoint [23] 354805 0
At 12 months postpartum
Secondary outcome [24] 354878 0
Maternal vascular function measure: an ultrasound of the carotid arteries
Timepoint [24] 354878 0
At 12 months postpartum (comparison between 6 month and 12 months postpartum values)

Eligibility
Key inclusion criteria
Have given birth at one of the study hospitals during the study period.
The index pregnancy was complicated by a hypertensive disorder of pregnancy: preeclampsia (PE), gestational hypertension (GH), chronic hypertension ± superimposed PE
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Plan to move out of study area/known unavailability to follow-up during study period
Active severe mental health condition or developmental disability precluding informed consent.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomised using REDCap software. Researchers at each of the study sites will have access to REDCap for randomisation and data entry of study participants (but not access to the randomisation block details). Allocation concealment is ensured, as the randomisation code will not be released until after baseline questionnaires have been completed and the study researcher then accesses REDCap for randomisation to Group 1, 2 or 3.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomly assigned to Group 1, 2 or 3 with a 1:1:1 allocation as per a computer generated randomisation schedule. Randomisation will be stratified by site, parity (1 versus >1) and body mass index (<30 versus 30+), using blocks. The block sizes will not be disclosed, to ensure concealment. Details relating to block randomisation will be kept in a separate document not available to anyone who is involved in trial recruitment.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Due to the nature of the intervention, neither postpartum clinic staff nor participants can be blinded to allocation.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
There are six primary hypotheses resulting from an all-pairwise comparison of the three study groups (two intervention groups and control) in the two primary outcomes of 1) maternal systolic BP 2) binary threshold on maternal weight and/or waist circumference change from 6-12 months postpartum.
The three primary hypotheses relating to primary outcome 1 (BP) will be incorporated into an ANOVA model, with those relating to outcome 2 (composite measure) into a logistic regression model. The model fit statistics (F-test and t-test) from each of the models will be used to determine (with a threshold of alpha = 0.05) whether the relevant elementary hypotheses should be evaluated. If the threshold is met, the R package multcomp, will be used in order to test the relevant elementary hypothesis while controlling the familywise type I error rate at alpha = 0.05.

This approach allows simultaneous inferences to be made over both parametric models and all relevant hypotheses, while accounting for correlation between the test statistics and allowing for stepwise testing procedures. All (three or six) tests that pass to the second stage of testing will be considered to be one family of tests and tested as two-sided and based on a null hypothesis of no treatment effect. A multiplicity adjusted p-value of less than 0.05 will be considered significant in any of the tests for the primary outcomes.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
21/01/2019
Actual
21/01/2019
Date of last participant enrolment
Anticipated
30/06/2022
Actual
27/07/2022
Date of last data collection
Anticipated
31/08/2022
Actual
24/08/2022
Sample size
Target
480
Accrual to date
Final
484
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 12523 0
St George Hospital - Kogarah
Recruitment hospital [2] 12524 0
Royal Hospital for Women - Randwick
Recruitment hospital [3] 12525 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [4] 12526 0
Campbelltown Hospital - Campbelltown
Recruitment hospital [5] 12527 0
Liverpool Hospital - Liverpool
Recruitment hospital [6] 19803 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 24904 0
2217 - Kogarah
Recruitment postcode(s) [2] 24905 0
2031 - Randwick
Recruitment postcode(s) [3] 24906 0
2050 - Camperdown
Recruitment postcode(s) [4] 24907 0
2560 - Campbelltown
Recruitment postcode(s) [5] 24908 0
2170 - Liverpool
Recruitment postcode(s) [6] 34452 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 301060 0
Government body
Name [1] 301060 0
New South Wales Department of Health Translational Research Grants Scheme
Country [1] 301060 0
Australia
Primary sponsor type
Individual
Name
Dr Amanda Henry
Address
Department of Women's and Children's Health
Level 2
Prichard Wing
St George Hospital
Gray Street
Kogarah NSW 2217
Country
Australia
Secondary sponsor category [1] 300922 0
Individual
Name [1] 300922 0
Professor Mark Brown
Address [1] 300922 0
Division of Medicine
St George Hospital
Gray Street
Kogarah NSW 2217
Country [1] 300922 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 301814 0
South Eastern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 301814 0
Ethics committee country [1] 301814 0
Australia
Date submitted for ethics approval [1] 301814 0
28/08/2018
Approval date [1] 301814 0
25/10/2018
Ethics approval number [1] 301814 0
18/193 (HREC/18/POWH/401)

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 88202 0
A/Prof Amanda Henry
Address 88202 0
Department of Women's and Children's Health
Level 2
Prichard Wing
St George Hospital
gray Street
Hogarth NSW 2217
Country 88202 0
Australia
Phone 88202 0
+612 91132315
Fax 88202 0
+612 91133901
Email 88202 0
amanda.henry@unsw.edu.au
Contact person for public queries
Name 88203 0
Lynne Roberts
Address 88203 0
1 South maternity
St George Hospital
Gray Street
Kogarah NSW 2217
Country 88203 0
Australia
Phone 88203 0
+612 91132117
Fax 88203 0
+612 91133642
Email 88203 0
lynne.roberts2@health.nsw.gov.au
Contact person for scientific queries
Name 88204 0
Amanda Henry
Address 88204 0
Department of Women's and children's Health
Level 2
Prichard Wing
St George Hospital
gray Street
Hogarth NSW 2217
Country 88204 0
Australia
Phone 88204 0
+612 91132315
Fax 88204 0
+612 91133901
Email 88204 0
amanda.henry@unsw.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All of the individual participant data collected during the trial, after de-identification, will be available for use in future IPD meta-analysis with national and international colleagues who may perform intervention trials for women after hypertensive pregnancy.
When will data be available (start and end dates)?
Beginning 6 months after publication of trial results, no end date.
Available to whom?
Case by case basis at the discretion of the primary sponsor.
Available for what types of analyses?
Data will be available to achieve the aims in the approved proposal, and for IPD meta-analyses.
How or where can data be obtained?
Access subject to approval by Principal Investigator


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
455Informed consent form  lynne.roberts2@health.nsw.gov.au Current PISCF available from ANZCTR site 376286-(Uploaded-01-06-2022-11-07-05)-Study-related document.doc
456Ethical approval  lynne.roberts2@health.nsw.gov.au Ethics approval letter available from ANZCTR site 376286-(Uploaded-23-11-2018-12-05-55)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe Association between Nutrition, Physical Activity, and Cardiometabolic Health at 6 Months following a Hypertensive Pregnancy: A BP2 Sub-Study.2023https://dx.doi.org/10.3390/nu15153294
N.B. These documents automatically identified may not have been verified by the study sponsor.